Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024 Nov 15:396:578464].

Yingkai Li , Pei Chen , Xin Huang , Hao Huang , Qian Ma , Zhongqiang Lin , Li Qui , Changyi Ou , Weibin Liu

J Neuroimmunol

Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address:

Published: March 2025

Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

Download full-text PDF
Source

http://dx.doi.org/10.1016/j.jneuroim.2025.578526 DOI Listing

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jneuroim.2025.578526	DOI Listing

Publication Analysis

Top Keywords

corrigendum "pathogenic

"pathogenic th17

th17 cells

cells potential

potential therapeutic

therapeutic target

target tacrolimus

tacrolimus achr-myasthenia

achr-myasthenia gravis

gravis patients"

A PHP Error was encountered